Patent No. EP2493466 (titled "Novel Antitumoral Use Of Cabazitaxel") was filed by Aventis Pharma on Oct 27, 2010. The application was issued on Mar 10, 2021.
Latest UPC cases involving this patent.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.